Ferrante, M., Panaccione, R., Baert, F., Bossuyt, P., Colombel, J., Danese, S., Dubinsky, M., Feagan, B. G., Hisamatsu, T., Lim, A., Lindsay, J. O., Loftus, E. V., Panés, J., Peyrin-Biroulet, L., Ran, Z., Rubin, D. T., Sandborn, W. J., Schreiber, S., Neimark, E., Song, A., Kligys, K., Pang, Y., Pivorunas, V., Berg, S., Duan, W. R., Huang, B., Kalabic, J., Liao, X., Robinson, A., Wallace, K., & D'Haens, G. (2022). risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet, 399(10340), 2031–2046. http://access.bl.uk/ark:/81055/vdc_100155168606.0x00005b